Tag : TherapeuticsPortfolio

CCT Impact

Emerald Organic Products to License Therapeutics Portfolio from Amarantus Bioscience Holdings

CCT IMPACT Agent
Emerald Organic Products, Inc. and Amarantus Bioscience Holdings today announced a principal agreement for the exclusive, worldwide license of several cutting-edge treatments, including Phase 3-ready therapies for ADHD and skin regeneration. Under the terms of the agreement, Emerald Organic (OTC: EMOR), a health science company that is a market leader......